跳至主要内容
临床试验/NCT05495958
NCT05495958Unknown2 期

The Efficacy and Safety of Topical Vitamin D Drop on Meibomian Gland Function in Patients With Meibomian Gland Dysfunction

Shahid Beheshti University of Medical Sciences1 个研究点 分布在 1 个国家目标入组 56 人开始时间: 2022年7月25日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
2 期
入组人数
56
试验地点
1
主要终点
Ocular Surface Disease Index score

研究概览

简要总结

In this randomized clinical trial, patients with Meibomian gland dysfunction aged 50 year and more will be enrolled. The Meibomian gland dysfunction diagnosis will confirmed by a cornea specialist. The enrolled patients will be randomly allocated to the treatment and placebo group. The patients in treatment group will receive topical vitamin D every 6 hours daily (25 Microgram/cc or 1000 IU). The control group will receive the same-shape packed drop without vitamin D. The patients in both group will receive the conventional treatment including hot compress and shampoo scrub.

The primary outcome is the change in Ocular surface disease index and 5-Item Dry Eye Questionnaire score assessed before the topical treatment and every one-months until 3 months. The secondary outcome measures are Tear breakup time, Schirmer test, Corneal fluorescein staining, Meibomian gland expressibility.

The grader and the patients will blind to the study group.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double (Participant, Care Provider)

入排标准

年龄范围
50 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • patients aged more than 50 years old and suffering from dry eye caused by meibomian gland dysfunction.

排除标准

  • Patients with Vitamin D deficiency
  • Patients taking Vitamin D systemic Supplementation
  • Patient with prior ocular surgeries within previous 6 months.
  • Patient with other causes of dry eye, such as aqueous tear deficiency or ocular surface disease

研究组 & 干预措施

Prescribe topical placebo eye drop

Placebo Comparator

干预措施: Topical placebo eye drop (Drug)

Prescribe topical Vitamin D eye drop

Active Comparator

干预措施: Topical Vitamin D eye drop (Drug)

结局指标

主要结局

Ocular Surface Disease Index score

时间窗: 3 months

The standard questionnaires.

次要结局

  • Tear breakup time (TBUT)(3 months)
  • schirmer1(3 months)
  • Fluorescein staining test(3 months)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Zahra Rabbani Khah

Head of Ophthalmic Research Center

Shahid Beheshti University of Medical Sciences

研究点 (1)

Loading locations...

相似试验